Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neural Basis of Depression in Parkinson's Disease
NCT06402955Phase 2Recruiting
- Sponsor
- Yale University
- Start
- Sep 2024
- Primary completion
- Jan 2029
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of ketamine in major depressive disorder (MDD), sponsored by Yale University. Started Sep 2024; status: recruiting.
02
Drugs
ketamine
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT06402955.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06402955.